3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
Cyclophosphamide
38
fludarabine
30
Rituximab
26
obinutuzumab
10
Bendamustine Hydrochloride
10
fludarabine phosphate
9
pembrolizumab
8
Specimen Handling
7
Etoposide
7
venetoclax
6
Vincristine
6
Prednisone
6
Magnetic Resonance Spectroscopy
6
Leukapheresis
6
Lenalidomide
6
ibrutinib
5
Inotuzumab Ozogamicin
5
Immunotherapy, Adoptive
5
Doxorubicin
5
Biopsy
5
ublituximab
4
tazemetostat
4
glofitamab
4
Interleukin-2
4
Dexamethasone
4
Cytarabine
4
pomalidomide
3
polatuzumab vedotin
3
Radiation
3
Nivolumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, B-Cell
×
ALT-803
×
Clear all
NCT07049432
2026-04-01
CARMEN-803
University of Utah
Phase 1
Withdrawn